Linked Life Data

15387111

Source:http://linkedlifedata.com/resource/pubmed/id/15387111

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2004-9-24
pubmed:abstractText
Cedars Sinai Medical Center has developed a protocol using high-dose (2 mg/kg) IVIG to desensitize and transplant patients who are broadly sensitized to HLA antigens. Since 2000, we have evaluated and transplanted 57 broadly sensitized patients (19 with deceased donor and 38 with living donor kidneys) following IVIG treatment. The incidence of allograft rejection was 38.5% and 4-year patient and graft survival rates were 96.5% and 82.5%, respectively. We have also used IVIG in combination with pulse steroids to treat antibody-mediated rejection episodes in 18 patients with C4d deposition in rejection biopsies. Thirteen responded to treatment and 5 grafts were lost in this group with severe antibody-mediated rejection. These results suggest that in many cases high-dose IVIG treatment can neutralize or mitigate antibody responses to eliminate positive donor-specific crossmatches and permit transplantation of broadly sensitized patients and offers a means to treat antibody-mediated rejection successfully.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0890-9016
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
193-8
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience.
pubmed:affiliation
Renal Transplant Program, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, USA.
pubmed:publicationType
Journal Article, Review